Entering a New Era of Opportunity for APOL1-Mediated Kidney Disease (AMKD): Connecting Genetic Screening to Clinical Trials for Breakthrough Therapies

APOL1-mediated kidney disease (AMKD) is responsible for over one-third of end-stage kidney disease (ESKD) cases in individuals of African ancestry. As multiple therapies for AMKD advance through late-stage clinical trials, including studies enrolling both adolescents and adults, timely identification of at-risk patients presents an unprecedented opportunity to improve outcomes. Tune in to this recording of an expert-led webinar to learn how to recognize risk factors for AMKD, implement genetic screening in practice, and evaluate opportunities for patient participation in ongoing clinical trials of emerging therapies. Access the downloadable AMKD Genetic Screening Guide featuring practical guidance to help identify at-risk patients and support them through the genetic testing process. Don’t miss this opportunity to expand your knowledge and help advance timely access to care for individuals affected by AMKD.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Target Specialties

Pricing

Free

Reported to ACCME by the provider

On-demand / recorded video
Credit · Up to 0.5 credits
Commercial Support

Released

Oct 31, 2025
Last day to claim credit

Oct 31, 2026 3 weeks left

Entering a New Era of Opportunity for APOL1-Mediated Kidney Disease (AMKD): Connecting Genetic Screening to Clinical Trials for Breakthrough Therapies

Related courses

More from PRIME Education, Inc. (PRIME®)